Lucid Genetics, Corp.

lucidgenes.com

Lucid Genetics is a clear way of understanding your body's genetic code and how it relates to your current and future health. Now, no matter where you are, you can meet with one of our boarded physicians to discuss a disease that has been in your family, an undiagnosed rare disease or your own history with a specific condition. From this live one on one meeting we can decide what genetic tests would be right for you.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

CENTOGENE LAUNCHES NEW CENTOGENOME®, WORLD’S MOST COMPREHENSIVE WHOLE GENOME SEQUENCING SOLUTION FOR DIAGNOSIS OF RARE AND NEURODEGENERATIVE DISEASES

Globenewswire | April 13, 2023

news image

Centogene N.V. the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay. Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options. Serving as a first-line test, NEW CentoGenome is the most comprehensive commercially avai...

Read More

Cell and Gene Therapy, Industrial Impact

ROCKET PHARMACEUTICALS' RP-A501 RECEIVES FDA RMAT DESIGNATION

Rocket Pharmaceuticals, Inc | February 09, 2023

news image

On February 7, 2023, Rocket Pharmaceuticals Inc., a renowned late-stage biotech firm advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet needs, announced that FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, the company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease, a life-threatening genetic cardiac disease with no disease-altering therapies available. RMAT s...

Read More

Cell and Gene Therapy

ELEVATEBIO AND THE UNIVERSITY OF PITTSBURGH ANNOUNCE CREATION OF PITT BIOFORGE BIOMANUFACTURING CENTER AT HAZELWOOD GREEN

ElevateBio | August 26, 2022

news image

ElevateBio, LLC and the University of Pittsburgh announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies. Through this agreement, ElevateBio will locate one of its next BaseCamp process development and Good Manufacturing Practice manufacturing facilities in Pittsburgh, fully equipped with its enabling technologies, including gene editing, induced pluripotent stem cell and cell, vector, and protein engineer...

Read More

CAMENA BIOSCIENCE HITS DNA SYNTHESIS MILESTONE

Labiotech | February 06, 2020

news image

Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....

Read More
news image

MedTech, Industrial Impact

CENTOGENE LAUNCHES NEW CENTOGENOME®, WORLD’S MOST COMPREHENSIVE WHOLE GENOME SEQUENCING SOLUTION FOR DIAGNOSIS OF RARE AND NEURODEGENERATIVE DISEASES

Globenewswire | April 13, 2023

Centogene N.V. the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay. Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options. Serving as a first-line test, NEW CentoGenome is the most comprehensive commercially avai...

Read More
news image

Cell and Gene Therapy, Industrial Impact

ROCKET PHARMACEUTICALS' RP-A501 RECEIVES FDA RMAT DESIGNATION

Rocket Pharmaceuticals, Inc | February 09, 2023

On February 7, 2023, Rocket Pharmaceuticals Inc., a renowned late-stage biotech firm advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet needs, announced that FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, the company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease, a life-threatening genetic cardiac disease with no disease-altering therapies available. RMAT s...

Read More
news image

Cell and Gene Therapy

ELEVATEBIO AND THE UNIVERSITY OF PITTSBURGH ANNOUNCE CREATION OF PITT BIOFORGE BIOMANUFACTURING CENTER AT HAZELWOOD GREEN

ElevateBio | August 26, 2022

ElevateBio, LLC and the University of Pittsburgh announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies. Through this agreement, ElevateBio will locate one of its next BaseCamp process development and Good Manufacturing Practice manufacturing facilities in Pittsburgh, fully equipped with its enabling technologies, including gene editing, induced pluripotent stem cell and cell, vector, and protein engineer...

Read More
news image

CAMENA BIOSCIENCE HITS DNA SYNTHESIS MILESTONE

Labiotech | February 06, 2020

Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....

Read More